glp 1 drugs kidney disease SGLT2 vs GLP-1 for CKD: Which Is Better? GLP-1 Receptor Agonists in the

They also show promise for the treatment of many inflammatory diseases including asthma and inflammatory bowel disorders like Crohns disease and ulcerative colitis Diagram showing food stimulating the release of GLP-1 into the intestine and its effects on the brain, stomach and pancreas Importance In 2023 GLP-1 based drugs was named breakthrough of the year by Science , a prestigious American journal

10.1001/jama.2023.24945

doi: 10.1074/jbc.C300557200, PMID: [DOI] [PubMed] [Google Scholar] 108

In addition to immunosuppressive therapy, several traditional and recent therapies aimed at nephroprotection in patients with proteinuric chronic kidney disease are gaining importance in the setting of LN

New developments, such as dual and triple agonists that target the glucagon, GLP-1, and GIP receptors, promise better results

Fasting Plasma Glucose levels ( 3.30 1.14 mmol/L) and body weight ( 3.87 0.87%) were lowered under treatment with SAR425899